Search

Emedastine

Emedastine is an antihistamine used in eye drops to treat allergic conjunctivitis.

Brensocatib

[A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813] … [A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation.

Trazodone

receptor inhibitor (SNRIs) in the treatment of depression. … [T646] It was initially granted FDA approval in 1981.[L3484]

Fidanacogene elaparvovec

from week 12 to month 15 compared to an ABR of 4.43 for the pre-treatment period. … [A32552] Disease severity is linked to the level of factor IX activity in the blood plasma, ranging from increased bleeding after injuries and surgical operations to spontaneous bleeding, hemorrhages in

Encorafenib

Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin … melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Pyrophosphoric acid

Tropicamide

[A229958] It is also used in combination with [hydroxyamphetamine] for the same indication. … Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors.

Pegvaliase

Food and Drug Administration and European Medicines Agency approved pegvaliase-pqpz in May 2018 for the treatment of adult patients with phenylketonuria (PKU). … Phenylketonuria is a rare autosomal recessive disorder that is characterized by deficiency of the enzyme phenylalanine hydroxylase (PAH) [A33284] and affects about 1 in 10,000 to 15,000 people in the United

Efinaconazole

It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia. … Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.

Vemurafenib

After approval, Roche in collaboration with Genentech launched a broad development program. [L1012] … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.